Sign in

You're signed outSign in or to get full access.

Brian Jackman

VP - Marketing at ENCISION
Executive

About Brian Jackman

Brian J. Jackman is Encision’s Vice President of Marketing (since February 2019) and has been with the company since 2006. He holds a B.S. in Mechanical Engineering from the University of Colorado at Boulder and is credited with several patents for laparoscopic surgical instruments; his responsibilities include national accounts and leadership across marketing, sales, device design, and program management . As of March 31, 2025, he was 43 years old . Company-level pay-versus-performance data indicate cumulative TSR values of $61.76, $75.00, and $70.00 for FY 2023–FY 2025, respectively, and the proxy notes compensation is not directly tied to Net Income/Loss; equity awards (stock options) are used to align with shareholder experience .

Past Roles

OrganizationRoleYearsStrategic Impact
Encision Inc.Senior Engineering Program Manager2009–2012Led engineering programs; contributed to surgical device design and patents
Encision Inc.Marketing Manager2012–2014Advanced product marketing and positioning
Encision Inc.Director of Marketing2014–2019Directed marketing strategy; national accounts oversight
Encision Inc.VP of MarketingFeb 2019–presentLeads marketing and national accounts; cross-functional leadership in sales/design

Fixed Compensation

MetricFY 2023FY 2024FY 2025
Salary ($)$161,236 $161,477 $155,695
Bonus ($)$0 $0 $0
Stock Awards ($)$0 $0 $0
Option Awards ($)$5,660 $0 $10,939
All Other Compensation ($)$0 $0 $0
Total ($)$166,896 $161,477 $166,634

Performance Compensation

Option Grants

NameGrant DateOptions (#)Exercise Price ($/Sh)Grant-Date Fair Value ($)
Brian J. Jackman05/01/202440,000 0.37 $9,611
Brian J. Jackman11/14/20245,000 0.42 $1,328

Equity grant timing disclosure shows the 11/14/2024 grant occurred outside four business days before and one business day after filings; market price change around disclosure was −4.7% .

Options Exercised

Fiscal YearOptions Exercised (#)Value Realized ($)
FY 202440,000 $4,180
FY 20251,500 $750

Outstanding Options (as of March 31, 2025)

Exercisable (#)Unexercisable (#)Exercise Price ($/Sh)Expiration
5,000 833 0.55 05/25/2025
9,167 3,167 0.50 11/12/2025
6,833 8,000 1.40 01/13/2027
7,000 40,000 0.51 02/09/2028
5,000 0.37 08/01/2029
0.42 02/14/2030

Vesting schedules are not disclosed in detail; mix of exercisable and unexercisable options indicates ongoing vesting under the 2014 Equity Incentive Plan administered by the Compensation Committee .

Equity Ownership & Alignment

Date (Record)Beneficial Shares% of ClassOptions Exercisable within 60 Days (Included Above)
June 17, 202445,654 0.38% Not itemized for Jackman in 2024 table
June 23, 202539,417 0.33% 35,917
  • Insider trading policy expressly prohibits derivative transactions and highlights risks of pledging or margin accounts; no Rule 10b5-1 plans were in effect for executive officers during FY 2025 .
  • No stock ownership guidelines, pledging disclosures specific to Jackman, or hedging exceptions are provided beyond policy-level prohibitions .

Employment Terms

  • No individual employment agreement, severance, or change-in-control terms are disclosed for Brian Jackman in reviewed proxy materials; the proxy describes CEO agreement terms only (auto-renewal, revenue and net income growth bonus pool mechanics, severance up to 1x base, and a $50,000 CoC bonus for the CEO) .
  • Company-level policy on trading/hedging/pledging applies to executives; equity grant timing is not coordinated with material nonpublic disclosures per policy .
  • Section 16(a) compliance: two late Forms 4 were filed by Brian Jackman in FY 2025, per the proxy’s compliance disclosure .

Say-on-Pay & Shareholder Feedback

ProposalForAgainstAbstainBroker Non-Votes
2025 Advisory Vote on Executive Compensation7,341,220 301,521 9,365 2,315,970
Frequency of Future Advisory Votes1 Year2 Years3 YearsAbstain
2025 Frequency Selection2,498,180 102,005 5,005,296 46,625

Compensation Structure Observations

  • Year-over-year mix: FY 2024 compensation was entirely cash salary with no option awards; FY 2025 introduced option grants ($10,939 grant-date fair value), modestly increasing at-risk pay vs prior year while fixed salary decreased slightly .
  • No annual cash bonus or RSU/PSU programs are disclosed for Jackman, indicating equity incentives primarily via stock options rather than performance share units .
  • Company disclosure states compensation is not directly tied to Net Income/Loss; alignment is sought via stock options and overall shareholder experience (TSR) .

Investment Implications

  • Alignment: Jackman’s equity exposure is mainly options with staggered expirations through 2030; recent grants at low exercise prices (0.37–0.42) create upside alignment with shareholders if the stock appreciates, though lack of explicit PSU metrics limits pay-for-performance precision .
  • Selling pressure: Executable options within 60 days totaled 35,917 at the June 23, 2025 record date, and he exercised 1,500 options in FY 2025 vs 40,000 in FY 2024; the FY 2025 proxy indicates no 10b5-1 plan in effect, reducing programmatic selling risk but some discretionary sales may occur around expirations .
  • Retention risk: Absence of disclosed employment/severance/change-in-control protections for Jackman suggests standard at-will arrangements; retention relies on ongoing equity incentives under the 2014 Plan rather than contractual economics .
  • Governance/compliance: Two late Forms 4 for Jackman represent a minor compliance flag; company-level prohibitions on hedging/derivatives and pledging risks are explicit, which is positive for alignment .
  • Shareholder sentiment: Strong say-on-pay support in 2025 and selection of a three-year advisory vote cycle indicate investor acceptance of the compensation framework; however, the small absolute size of NEO compensation and limited performance-based metrics (beyond options) should be monitored for future alignment as strategy evolves .